ABCG2-meditated multidrug resistance and tumor-initiating capacity of side population cells from colon cancer

Oncology Research and Treatment

Volumn 37, Issue 11, 2014, Pages 666-672

  Xie, Zheng Yuan ^a   Lv, Ke ^b   Xiong, Ying ^a   Guo, Wu Hua ^a  

^a NANCHANG UNIVERSITY   (China)

^b EAST CHINA JIAOTONG UNIVERSITY   (China)

Author keywords

Cancer stem cells; Chemotherapy; Drug resistance; Side population cells; Tumor invasion

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CD133 ANTIGEN; CD147 ANTIGEN; EPITHELIAL CELL ADHESION MOLECULE; HERMES ANTIGEN; VERAPAMIL; ABC TRANSPORTER; ABCB1 PROTEIN, HUMAN; ABCG2 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; CISPLATIN; MULTIDRUG RESISTANCE PROTEIN; OXALIPLATIN; PACLITAXEL; PLATINUM COMPLEX; TUMOR MARKER; TUMOR PROTEIN;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER STEM CELL; CANCER TISSUE; CLINICAL ARTICLE; COLON CANCER; CONTROLLED STUDY; FLUORESCENCE ACTIVATED CELL SORTING; FLUORESCENCE MICROSCOPY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOFLUORESCENCE; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SIDE POPULATION CELL; TUMOR GROWTH; TUMOR RECURRENCE; ANIMAL; CANCER TRANSPLANTATION; COLONIC NEOPLASMS; DRUG RESISTANCE; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETICS; INDIRECT FLUORESCENT ANTIBODY TECHNIQUE; MALE; METABOLISM; MIDDLE AGED; NONOBESE DIABETIC MOUSE; PATHOLOGY; PHYSIOLOGY; PROCEDURES; SCID MOUSE;

ADULT; ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BIOMARKERS, TUMOR; CISPLATIN; COLONIC NEOPLASMS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, INBRED NOD; MICE, SCID; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; ORGANOPLATINUM COMPOUNDS; P-GLYCOPROTEINS; PACLITAXEL; REAL-TIME POLYMERASE CHAIN REACTION; SIDE-POPULATION CELLS;

EID: 84913591595     PISSN: 22965270     EISSN: 22965262     Source Type: Journal    
DOI: 10.1159/000368842     Document Type: Article

References (19)

1. Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U, Goodell MA, Brenner MK: A distinct side population of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad USA 2004;101:14228-14233.
2. Robey RW, Shukla S, Finley EM, Oldham RK, Barnett D, Ambudkar SV, Fojo T, Bates SE: Inhibition of Pgp (ABCB1) and MDR associated protein-1 (ABCC1) mediate transport by the orally administered inhibitor CBT-1. Biochem Pharmacol 2008;75:1032-1042.
3. Greenlee RT, Hill-Harmon MB, Murray T, Thun M: Cancer statistics, 2001. CA Cancer J Clin 2001; 51:15-36.
4. O'Brien CA, Pollett A, Gallinger S, Dick JE: A human colon cancer cell capable of initiating tumor growth in immunodeficient mice. Nature 2007;445:106-110.
5. He QZ, Luo XZ, Wang K, Wang K, Zhou Q, Ao H, Yang Y, Li SX, Li Y, Zhu HT, Duan T: Isolation and characterization of cancer stem cells from highgrade serous ovarian carcinomas. Cell Physiol Biochem 2014;33:173-184.
6. Shi Y, Fu X, Hua Y, Han Y, Lu Y, Wang J: The side population in human lung cancer cell line NCIH460 is enriched in stem-like cancer cells. PLoS One 2012;7:e33358.
7. Dean M, Fojo T, Bates S: Tumor stem cells and drug resistance. Nat Rev Cancer 2004;5:275-284.
8. Eramo A, Ricci-Vitiani L, Zeuner A, Pallini R, Lotti F, Sette G, Pilozzi E, Larocca LM, Peschle C, De Maria R: Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ 2006;13:1238-1241.
9. Gil J, Stembalska A, Pesz KA, Sasiadek MM: Cancer stem cells: the theory and perspectives in cancer therapy. J Appl Genet 2008;49:193-199.
10. Patrawala L, Calhoun T, Schneider-Broussard R, Zhou J, Claypool K, Tang DG: Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2-cancer cells are similarly tumorigenic. Cancer Res 2005;65:6207-6219.
11. Tirino V, Desiderio V, Paino F, De Rosa A, Papaccio F, La Noce M, Laino L, De Francesco F, Papaccio G: Cancer stem cells in solid tumors: an overview and new approaches for their isolation and characterization. FASEB J 2013;27:13-24.
12. Baba T, Convery PA, Matsumura N, Whitaker RS, Kondoh E, Perry T, Huang Z, Bentley RC, Mori S, Fujii S, Marks JR, Berchuck A, Murphy SK: Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene 2009;28:209-218.
13. Silva IA, Bai S, McLean K, Yang K, Griffith K, Thomas D, Ginestier C, Johnston C, Kueck A, Reynolds RK, Wicha MS, Buckanovich RJ: Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res 2011;71:3991-4001.
14. Yanamoto S, Kawasaki G, Yoshitomi I, Iwamoto T: Clinicopathologic significance of EpCAM expression in squamous cell carcinoma of the tongue and its possibility as a potential target for tongue cancer gene therapy. Oral Oncol 2007;43:869-877.
15. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R: Identification and expansion of human colon-cancer-initiating cells. Nature 2007;445:111-115.
16. Guo H, Li R, Zucker S, Toole BP: EMMPRIN (CD147), an inducer of matrix metalloproteinase synthesis, also binds interstitial collagenase to the tumor cell surface. Cancer Res 2000;60:888-891.
17. Yanamoto S, Kawasaki G, Yoshitomi I, Iwamoto T, Hirata K, Mizuno A: Clinicopathologic significance of EpCAM expression in squamous cell carcinoma of the tongue and its possibility as a potential target for tongue cancer gene therapy. Oral Oncol 2007;43:869-877.
18. Dancescu M, Rubio-Trujillo M, Biron G, Bron D, Delespesse G, Sarfati M: Interleukin 4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates Bcl-2 expression. J Exp Med 1992;176:1319-1326.
19. Todaro M, Alea MP, Di Stefano AB, Cammareri P, Vermeulen L, Iovino F, Tripodo C, Russo A, Gulotta G, Medema JP, Stassi G: Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 2007;1:389-402.